drugset / Trial / NCT03785067
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study
RandomizedParallel-groupQuadruple-blindScreening
Summary
A Sub-Study of an investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial (TRIDENT) to determine the effect of more intensive long-term blood pressure control, provided by a fixed low-dose combination blood pressure lowering pill ("Triple Pill") strategy on top of standard of care, for slowing memory decline as measured by Cambridge Neuropsychological Test Automated Battery (CANTAB), in patients with a history of acute stroke due to intracerebral haemorrhage (ICH).
Timeline
- Start
- 2020-02-27
- Primary completion
- 2021-02-03
- Completion
- 2021-02-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amlodipine | Other / unclassified | 2.5 mg | Oral |
| Subject | Indapamide | Small molecule | 1.25 mg | Oral |
| Subject | Telmisartan | Other / unclassified | 20 mg | Oral |